{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:00:17Z","timestamp":1789390817074,"version":"build-2803163510"},"reference-count":16,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,16]]},"DOI":"10.18632\/oncotarget.16797","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T19:42:25Z","timestamp":1491248545000},"page":"33416-33421","source":"Crossref","is-referenced-by-count":11,"title":["Sequential evaluation of <i>CALR<\/i> mutant burden in patients with myeloproliferative neoplasms"],"prefix":"10.18632","volume":"8","author":[{"given":"Chiara","family":"Cavalloni","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia V.","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pietra","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Roncoroni","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bellini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ciboddo","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria C.","family":"Casetti","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Landini","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fugazza","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Troletti","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Astori","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy"},{"name":"Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Vardiman","year":"2016","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms","volume":"369","author":"Bagienski","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Hinton","year":"2013","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Bellini","year":"2014","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Vannucchi","year":"2014","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Cavalloni","year":"2014","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Pardanani","year":"2014","journal-title":"Leukemia"},{"key":"8","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Reilly","year":"2006","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Skoda","year":"2007","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Skoda","year":"2005","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2013-02-486050","article-title":"Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms","volume":"121","author":"Astori","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Kralovics","year":"2014","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/leu.2015.3","article-title":"Allelic imbalance in CALR somatic mutagenesis","volume":"29","author":"Kralovics","year":"2015","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2009-05-222331","article-title":"Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"114","author":"Boultwood","year":"2009","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34(+) cells into peripheral blood in myeloproliferative disorders","volume":"107","author":"Cazzola","year":"2006","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Roncoroni","year":"2016","journal-title":"Leukemia"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T19:16:07Z","timestamp":1589138167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":16,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,5,16]]}},"alternative-id":["16797","28422716"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16797","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]}}}